Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Description

This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.

Conditions

Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.

An Interventional Study of Letermovir for Secondary Prophylaxis After Treatment of Cytomegalovirus Infection in High Risk (D+/R-) Kidney and Kidney/Pancreas Transplant Recipients

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Condition
Cytomegalovirus Infections
Intervention / Treatment

-

Contacts and Locations

Madison

UW Hospital and Clinics, Madison, Wisconsin, United States, 53792

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * undergone kidney or simultaneous kidney/pancreas transplant
  • * high-risk CMV serostatus (D+/R-) at time of transplant
  • * develop CMV viremia that necessitates treatment per our institutional protocol (enrolled in the CMV stewardship monitoring initiative)
  • * demonstrate proven or presumptive lack of CMI, either by CMI testing or risk factor screening
  • * able to provide informed consent to participate
  • * contraindication to letermovir or its excipients
  • * develop ganciclovir-resistant CMV infection
  • * currently participating in any study involving the administration of a CMV vaccine or another CMV investigational agent
  • * unable or unwilling, in the opinion of the Investigator, to comply with the protocol
  • * pregnant or breastfeeding

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Wisconsin, Madison,

Margaret Jorgenson, PharmD, BCTXP, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

2026-09